Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Net Income towards Common Stockholders: 2020-2025

Historic Net Income towards Common Stockholders for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to -$45.1 million.

  • Maravai Lifesciences Holdings' Net Income towards Common Stockholders rose 73.87% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.8 million, marking a year-over-year increase of 33.91%. This contributed to the annual value of -$259.6 million for FY2024, which is 87.62% down from last year.
  • Maravai Lifesciences Holdings' Net Income towards Common Stockholders amounted to -$45.1 million in Q3 2025, which was up 35.48% from -$69.8 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' Net Income towards Common Stockholders' 5-year high stood at $156.7 million during Q2 2022, with a 5-year trough of -$172.5 million in Q3 2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$51.4 million, with a median of -$45.1 million in 2025.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Net Income towards Common Stockholders surged by 9,227.12% in 2021, and later crashed by 1,582.49% in 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' Net Income towards Common Stockholders (Quarterly) stood at $127.1 million in 2021, then slumped by 31.22% to $87.4 million in 2022, then plummeted by 225.80% to -$110.0 million in 2023, then soared by 58.11% to -$46.1 million in 2024, then spiked by 73.87% to -$45.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$45.1 million for Q3 2025, versus -$69.8 million for Q2 2025 and -$52.9 million for Q1 2025.